Hormonal and metabolic changes induced by flunarizine therapy: preliminary results.
The effect of 30-days of flunarizine (5 mg/day) therapy on pituitary, B-pancreatic, gonadic and adrenal function was studied in five adolescents with common migraine. Baseline concentration of growth hormone was significantly reduced after flunarizine therapy. The response of prolactin to thyrotrophin-releasing hormone was significantly increased after flunarizine therapy. The percentages of HbA1 and HbA1c were significantly higher after flunarizine therapy. The drug had no apparent effect on gonadic and adrenal function. Further studies are needed to confirm the effect of flunarizine on the hypothalamus-pituitary axis and glucose tolerance.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000097:blood; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002648:Child; D002936:Cinnarizine / Q000031:analogs & derivatives / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005444:Flunarizine; D006442:Glycated Hemoglobin / Q000032:analysis; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000097:blood / Q000188:drug therapy*; D010879:Piperazines / Q000494:pharmacology*; D010907:Pituitary Hormones / Q000097:blood*
D000305:Adrenal Cortex Hormones; D002121:Calcium Channel Blockers; D002936:Cinnarizine; D005444:Flunarizine; D006442:Glycated Hemoglobin; D012739:Gonadal Steroid Hormones; D010879:Piperazines; D010907:Pituitary Hormones